Free Trial

Oncobiologics (OTLK) Stock Price, News & Analysis

Oncobiologics logo
$1.60 -0.15 (-8.57%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$1.66 +0.06 (+3.75%)
As of 06/27/2025 05:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Oncobiologics Stock (NASDAQ:OTLK)

Key Stats

Today's Range
$1.60
$1.80
50-Day Range
$1.41
$2.03
52-Week Range
$0.87
$9.25
Volume
2.90 million shs
Average Volume
821,645 shs
Market Capitalization
$53.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.60
Consensus Rating
Moderate Buy

Company Overview

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Oncobiologics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
48th Percentile Overall Score

OTLK MarketRank™: 

Oncobiologics scored higher than 48% of companies evaluated by MarketBeat, and ranked 614th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Oncobiologics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Oncobiologics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Oncobiologics' stock forecast and price target.
  • Earnings Growth

    Earnings for Oncobiologics are expected to grow in the coming year, from ($2.27) to ($0.20) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Oncobiologics is -1.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Oncobiologics is -1.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Oncobiologics' valuation and earnings.
  • Percentage of Shares Shorted

    12.91% of the float of Oncobiologics has been sold short.
  • Short Interest Ratio / Days to Cover

    Oncobiologics has a short interest ratio ("days to cover") of 4.7.
  • Change versus previous month

    Short interest in Oncobiologics has recently decreased by 14.91%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Oncobiologics does not currently pay a dividend.

  • Dividend Growth

    Oncobiologics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.91% of the float of Oncobiologics has been sold short.
  • Short Interest Ratio / Days to Cover

    Oncobiologics has a short interest ratio ("days to cover") of 4.7.
  • Change versus previous month

    Short interest in Oncobiologics has recently decreased by 14.91%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Oncobiologics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.94 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Oncobiologics this week, compared to 3 articles on an average week.
  • Search Interest

    Only 10 people have searched for OTLK on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Oncobiologics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Oncobiologics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.80% of the stock of Oncobiologics is held by insiders.

  • Percentage Held by Institutions

    Only 11.20% of the stock of Oncobiologics is held by institutions.

  • Read more about Oncobiologics' insider trading history.
Receive OTLK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncobiologics and its competitors with MarketBeat's FREE daily newsletter.

OTLK Stock News Headlines

3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring.
See More Headlines

OTLK Stock Analysis - Frequently Asked Questions

Oncobiologics' stock was trading at $1.89 on January 1st, 2025. Since then, OTLK shares have decreased by 15.3% and is now trading at $1.60.
View the best growth stocks for 2025 here
.

Oncobiologics, Inc. (NASDAQ:OTLK) issued its quarterly earnings data on Thursday, May, 15th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.55) by $0.15.

Shares of Oncobiologics reverse split on the morning of Thursday, March 14th 2024.The 1-20 reverse split was announced on Thursday, March 14th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Top institutional shareholders of Oncobiologics include Goldman Sachs Group Inc. (0.32%) and AQR Capital Management LLC (0.26%). Insiders that own company stock include Jeff Evanson, Terry Dagnon, Kurt J Hilzinger, Lawrence A Kenyon and Yezan Munther Haddadin.
View institutional ownership trends
.

Shares of OTLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oncobiologics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Moderna (MRNA), Intel (INTC) and Sorrento Therapeutics (SRNE).

Company Calendar

Last Earnings
5/15/2025
Today
6/28/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
9/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:OTLK
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.60
High Stock Price Target
$21.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+500.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$75.37 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
($3.09) per share
Price / Book
-0.52

Miscellaneous

Free Float
31,957,000
Market Cap
$53.71 million
Optionable
Optionable
Beta
0.31
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:OTLK) was last updated on 6/29/2025 by MarketBeat.com Staff
From Our Partners